olfactory receptor family 1 subfamily L member 3Genealiases: OR9-28 · OR9-D
Q-omics provides the consensus-scored OR1L3 profile across patient tissues and cancer cell-line models. OR1L3 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, OR1L3 is differentially expressed in 2, with the highest sampling consensus in PRAD. Additionally, OR1L3 RNA expression shows 9,482 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight THCA, PRAD, and THYM as cancer lineages where OR1L3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR1L3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR1L3 survival associations across molecular data types. OR1L3 RNA expression shows survival associations in the most cancer types (10), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR1L3 RNA expression–survival associations across cancer types. High OR1L3 expression shows unfavorable associations in THCA, COAD and KIRC, but favorable associations in ESCA, UCEC and CESC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify THCA as the clearest survival context for OR1L3 RNA expression.
This table summarizes OR1L3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for OR1L3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR1L3 shows lower tumor expression in COAD and higher tumor expression in PRAD. The PRAD box plot shows higher OR1L3 RNA expression in tumor versus normal tissue (log2 FC = +0.019, t-test p = .043).
This table shows molecular features associated with OR1L3 in patient tissues and cancer cell lines. In patient samples, OR1L3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, OR1L3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
